Kura Oncology (KURA) Operating Leases (2020 - 2026)

Kura Oncology (KURA) has 7 years of Operating Leases data on file, last reported at $13.2 million in Q1 2026.

• Quarterly Operating Leases rose 68.08% year-over-year to $13.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.2 million (up 68.08% YoY) and the FY2025 annual result came in at $9.5 million, up 82.45% from the prior year.
• Operating Leases improved to $13.2 million in Q1 2026 per KURA's latest filing, from $9.5 million in the prior quarter.
• Across five years, Operating Leases topped out at $13.2 million in Q1 2026 and bottomed at $1.5 million in Q2 2023.
• The 5-year median for Operating Leases is $5.8 million (2024), against an average of $5.9 million.
• The widest annual swing landed in 2023, when Operating Leases slumped 59.61%; it then surged 301.58% in 2024.
• Tracing KURA's Operating Leases over 5 years: stood at $2.5 million in 2022, then soared by 149.69% to $6.4 million in 2023, then decreased by 18.42% to $5.2 million in 2024, then surged by 82.45% to $9.5 million in 2025, then jumped by 39.84% to $13.2 million in 2026.
• Per Business Quant, the three latest KURA Operating Leases figures stand at $13.2 million (Q1 2026), $9.5 million (Q4 2025), and $8.4 million (Q3 2025).

Peer Comparison